肌层浸润性膀胱癌的辅助化疗:基于随机对照试验个体参与者数据的系统综述与Meta分析
该研究更新了基于个体参与者数据的系统综述与Meta分析,纳入10项随机对照试验共1183例肌层浸润性膀胱癌患者,发现以顺铂为基础的辅助化疗可改善总生存(HR=0.82,95%CI 0.70-0.96,p=0.02),5年绝对生存获益6%(从50%到56%),校正后绝对获益9%(HR=0.77,95%CI 0.65-0.92,p=0.004),并改善无复发生存、无局部区域复发生存和无转移生存。结论认为以顺铂为基础的辅助化疗是改善肌层浸润性膀胱癌结局的有效选择。
要点
- 以顺铂为基础的辅助化疗改善肌层浸润性膀胱癌总生存(HR=0.82,95%CI 0.70-0.96,p=0.02)。
- 5年绝对生存获益6%(从50%到56%),校正后绝对获益9%(HR=0.77,95%CI 0.65-0.92,p=0.004)。
- 无复发生存、无局部区域复发生存和无转移生存的绝对获益分别为11%、11%和8%。
核心结论
- 该系统综述与Meta分析表明,以顺铂为基础的辅助化疗是改善肌层浸润性膀胱癌结局的有效选择。
研究设计与样本
- 系统检索已发表和未发表的随机对照试验,集中收集、核查并分析更新的个体参与者数据,采用两阶段固定效应模型合并各随机对照试验结果,共纳入10项随机对照试验1183例参与者。
主要发现
- 10项随机对照试验(1183例参与者)分析显示,以顺铂为基础的辅助化疗改善总生存(HR=0.82,95%CI 0.70-0.96,p=0.02),5年绝对生存获益6%,从50%到56%。
- 校正年龄、性别、pT分期和pN分类后,绝对获益9%(HR=0.77,95%CI 0.65-0.92,p=0.004)。
- 未见明确证据表明疗效因试验或参与者特征而异。
- 辅助化疗改善无复发生存(HR=0.71,95%CI 0.60-0.83,p<0.001)、无局部区域复发生存(HR=0.68,95%CI 0.55-0.85,p<0.001)和无转移生存(HR=0.79,95%CI 0.65-0.95,p=0.01),绝对获益分别为11%、11%和8%。
临床怎么用
- 作者认为,以顺铂为基础的辅助化疗是改善肌层浸润性膀胱癌结局的有效选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Our prior systematic review and meta-analysis of individual participant data (IPD) suggesting a benefit of adjuvant chemotherapy for muscle-invasive bladder cancer was limited by the number and size of included randomised trials. We have updated results to include additional trials, providing the most up-to-date and reliable evidence of the effects of this treatment. OBJECTIVE: To investigate the role of adjuvant cisplatin-based chemotherapy in the treatment of muscle-invasive bladder cancer. EVIDENCE ACQUISITION: Published and unpublished trials were sought via searches of bibliographic databases, trials registers, conference proceedings, and hand searching. Updated IPD were centrally collected, checked, and analysed. Results from individual randomised controlled trials (RCTs) were combined using a two-stage fixed-effect model. Prespecified analyses explored any variation in effect by trial and participant characteristics. EVIDENCE SYNTHESIS: Analyses of ten RCTs (1183 participants) demonstrated a benefit of cisplatin-based adjuvant chemotherapy on overall survival (hazard ratio [HR] = 0.82, 95% confidence interval [CI] = 0.70-0.96, p = 0.02). This represents an absolute improvement in survival of 6% at 5 yr, from 50% to 56%, and a 9% absolute benefit when adjusted for age, sex, pT stage, and pN category (HR = 0.77, 95% CI = 0.65-0.92, p = 0.004). There was no clear evidence that the effect varied by trial or participant characteristics. Adjuvant chemotherapy was also shown to improve recurrence-free survival (HR = 0.71, 95% CI = 0.60-0.83, p < 0.001), locoregional recurrence-free survival (HR = 0.68, 95% CI = 0.55-0.85, p < 0.001), and metastasis-free survival (HR = 0.79, 95% CI = 0.65-0.95, p = 0.01), with absolute benefits of 11%, 11%, and 8%, respectively. CONCLUSIONS: This systematic review and meta-analysis demonstrates that cisplatin-based adjuvant chemotherapy is a valid option for improving outcomes for muscle-invasive bladder cancer. PATIENT SUMMARY: We looked at the effect of cisplatin-based chemotherapy on outcomes in participants with muscle-invasive bladder cancer. We gathered this information from eligible randomised controlled trials. We demonstrated that cisplatin-based chemotherapy is a valid option for improving outcomes of muscle-invasive bladder cancer.
引用
- Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials. Eur Urol. 2021. PMID: 34802798. doi:10.1016/j.eururo.2021.09.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。